Vertex taking ‘flexible’ approach to pricing talks for experimental CRISPR therapy
BioPharma Drive: Drug Pricing
AUGUST 2, 2023
The company is discussing various payment models for its sickle cell treatment with government and commercial insurers ahead of an FDA approval decision later this year.
Let's personalize your content